RAS Wild Type

8 registered clinical trials studyying RAS Wild Type.

Status	Trial	Sponsor	Phase
Terminated	Glutamine PET Imaging Colorectal Cancer NCT03275974	M.D. Anderson Cancer Center	Phase 1
Active Not Recruiting	Niraparib and Panitumumab in Patients With Advanced or Metastatic Colorectal Cancer NCT03983993	Emory University	Phase 2
Completed	Avelumab Plus Cetuximab in Pre-treated RAS Wild Type Metastatic Colorectal Cancer NCT04561336	University of Campania Luigi Vanvitelli	Phase 2
Terminated	5-FU Based Maintenance Therapy in RAS Wild Type Metastatic Colorectal Cancer After Induction With FOLFOX Plus NCT03300609	University of Southern California	Phase 3
Completed	Validation of a New Prognostic Score for Adult Patients With RAS Wild-type mCRC Treated With Vectibix® and FOL NCT03043950	iOMEDICO AG	—
Unknown	Optimization of Individualized Therapy for CRCs With Secondary RESISTance Towards Anti-EGFR Targeted Therapy U NCT03263663	PD Dr. med. Volker Heinemann	—
Completed	Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With RAS Wild-Type Locally Advanced NCT02292758	Academic and Community Cancer Research United	Phase 2
Unknown	Efficacy and Tolerance of Maintenance Therapy in Patients With Incurable Advanced Colorectal Cancer NCT02071069	Tianshu Liu	Phase 2